Dr. Nir Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research, a professor in the Departments of Medicine and Genetics, the director of the Institute for Aging Research at the Albert Einstein College of Medicine, the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging.

He is leading an international effort to approve drugs targeting aging. Targeting Aging with METformin (TAME) is a specific study designed to prove the concept that multi-morbidities of aging can be delayed by metformin; working with the FDA to approve this approach, which will serve as a template for future efforts to delay aging and its diseases in humans, and also has a biomarker arm. Dr. Barzilai is also the Scientific Director and on the board of the American Federation for Aging Research, where he leads its biomarker effort (FAST). He is the Executive of the Longevity Biotech Association (LBA) and on the Healthy Longevity Medicine Society council. He is also a founder of CohBar Inc. and LifeBioscience biotech. He authorizes Age Later: Health Span, Life Span, and the New Science of Longevity.